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Abstract 
Metabotropic glutamate receptors 2 and 3 (mGluR2/3) have been shown as efficient 
targets for antipsychotic intervention. We therefore investigated the receptor density 
of mGluR2/3 in the dorsolateral prefrontal cortex (dlPFC; Brodman area 46) of 
schizophrenia/schizoaffective patients (n=37) and matched controls (n=37) using 
receptor autoradiography. No difference in mGluR2/3 density was identified in 
relation to schizophrenia diagnosis. Overall and in individual groups, a negative 
correlation of mGluR2/3 density and age at death has been found. These and 
previous results suggest that density of mGluR2/3 in the dlPFC is less likely to impact 
on the efficiency of the mGluR2/3 agonist in treating schizophrenia symptoms. 
 
1. Introduction 
Schizophrenia is a highly complex brain disorder and its underlying mechanisms are 
still not understood. With the strong implication of glutamatergic neurotransmission, 
metabotropic glutamate receptors 2 and 3 (mGluR2/3) have been examined as 
potential new targets for antipsychotic treatment (Harrison et al. 2008; Krivoy et al. 
2008; Swanson et al. 2005). In both animal and human studies, the highly selective 
agonist for mGluR2/3, LY404039, was shown to have antipsychotic potential (Patil et 
al. 2007; Rorick-Kehn et al. 2007b). Intriguingly, no appreciable affinities for other 
glutamate receptor subtypes and transporters neither for non-glutamate receptors, 
such as dopamine or serotonin, were found for this compound (Rorick-Kehn et al. 
2007a). The efficiency and specificity of the mGluR2/3 agonist make alterations in the 
density of mGluR2/3 in schizophrenia-relevant brain regions highly likely.  
Cognitive impairments in schizophrenia have been associated with a dysfunction of 
the dorsolateral prefrontal cortex (dlPFC) (Callicott et al. 2000; Eisenberg and 
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Berman 2010); increased prefrontal glutamate concentrations have been found in a 
subgroup of schizophrenia patients (Olbrich et al. 2008). Using post-mortem brain 
tissue of schizophrenia patients an earlier study did not find changes in the protein 
expression of mGluR2/3 in the dlPFC (Crook et al. 2002). A recent study, however, 
showed a higher expression of mGluR2 than mGluR3 in the dlPFC and a lower 
expression of mGluR3 in the dlPFC of patients (Ghose et al. 2009); receptor binding 
density, however, has not been studied. 
We therefore studied mGluR2/3 density in post-mortem brain tissue of the patient 
cohort of the schizophrenia research institute (SRI) comprising 37 patients with 
schizophrenia diagnosis (including 7 schizoaffective patients) and 37 matched 
controls to identify the potential role of dlPFC mGluR2/3 in schizophrenia.  
 
2. Methods  
2. 1. Post-mortem brain tissue 
For the present study, post-mortem brain tissue of the dlPFC (Brodman Area 46) of 
37 schizophrenia/schizoaffective patients and 37 matched controls was used. All 
research was approved and conducted under the guidelines of the Human Research 
Ethics Committee at the University of Wollongong (HE99.222) and University of New 
South Wales (HREC 07261). Clinical assessments, selection of cases and matched 
controls, assessment of tissue quality and preparation of slide-mounted coronal 
tissue sections (14µm) were performed by the Tissue Resource Centre and the 
Schizophrenia Research Institute (Weickert et al. 2010). All experiments and analysis 
was done blind to the clinical details of each case.  
2.2. Receptor Autoradiography for mGluR2/3 density 
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Receptor autoradiography on mGluR2/3 was performed using [3H]LY354740 based 
on the protocol described previously (Richards et al. 2005). Two slides per case were 
pre-incubated for 2 x 10 min in a buffer solution (50mM Tris buffer, 2mM MgCl2, 2mM 
CaCl2; pH=7) at room temperature (RT). Thereafter, the slides were incubated for 60 
min at RT in buffer solution containing 50nM [3H]LY354740. As controls, adjacent 
brain sections of 6 selected cases (3 patients vs. 3 matched controls) were incubated 
with 50nM [3H]LY354740 in the presence of 0.01 mM DCG-IV to determine non-
specific binding. Following incubation the slides were washed in cold (4oC) washing 
buffer (50mM Tris buffer, pH7) for 2 x 30sec and 1 x 1 min.  
2. 3. Receptor density quantification 
Quantification was performed using the Beta-Imager and B vision+ program 
(BioSpace, France). Cortical regions were analysed according to histological 
standards (provided by Weickert et al, see Figure 1).  
Four schizophrenia cases (3 schizophrenia, 1 schizoaffective diagnosis) and 1 
control case were excluded from analysis as binding data deviated more than 30% of 
overall standard deviation. 
2. 4. Statistical Analysis 
All data was analysed using SPSS (17.0). Data was tested for normality (Lilliefors 
test) and homogeneity (Levene's test). Student's t-test was used to compare the 
levels of radioligand binding for schizophrenia/schizoaffective patients vs controls, 
schizophrenia patients vs controls, schizoaffective patients vs controls, 
schizoaffective vs schizophrenia patients as well as gender differences and manner 
of death. Bonferroni correction was used to correct for multiple testing in case of 
significance. Spearman's correlation was used to test for any effects of continuous 
descriptive variables including age at death, pH (prefrontal cortex), post mortem 
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interval (PMI), RNA integrity (RIN), freezer storage time, brain weight, brain volume, 
chlorpromazine equivalent (mg) of lowest, highest, lifetime and last recorded 
antipsychotic dose, antidepressant treatment, daily ethanol intake, smoking quantity, 
age of onset and duration of illness on receptor binding (for clinical data see 
(Weickert et al. 2010). ANCOVA analysis, controlling for age of death, was performed 
for obtained significances when using the the Student's t-test; levels of radioligand 
binding in suicidal vs naturally deceased schizophrenia/schizoaffective patients as 
well as patients on last recorded high (>450mg/day chlorpromazine equivalent) or 
low (<450mg/day chlorpromazine equivalent) dose of antipsychotics were therefore 
studied. Significance was accepted with p < 0.05. Data is presented as mean ± SEM. 
 
3. Results 
Independent of diagnosis, no difference was found between patients and controls in 
mGluR2/3 receptor density in the dlPFC. 
In all groups, schizophrenia patients (R=-0.62; p<0.01), schizoaffective patients (R=-
0.92:p<0.01), controls (R=-0.65; p<0.01) and overall cases (R=-0.66; p<0.01), there 
was a strong negative correlation between mGluR2/3 binding and age at death 
(Figure 2). 
In all cases and schizophrenia/schizoaffective patients only, mGluR2/3 binding 
additional correlated with pH, RIN, time of storage, brain weight, manner of death, 
antipsychotic dose (as chlorpromazine equivalent), duration of illness and smoking 
quantity. None of these correlations remained, however, significant after correcting 
these variables for age at death. The correlation of mGluR2/3 density and age at 
death remained significant when correcting for any of these variables. 
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Whereas suicide victims amongst schizophrenia/schizoaffective patients showed 
higher (17.1 ± 0.5; n=8) mGluR2/3 levels than patients dying from natural death (14.3 
± 0.7; n=26), this was only due to the young age when committing suicide rather than 
the manner of death (uncorrected F(32,1)=5.99; p<0.05; corrected for age at death 
F(30,1)=0.70; p=0.41). Similarly, whereas users of (on average in this cohort) low 
doses of antipsychotics (>450mg/day chlorpromazine equivalent) showed higher 
levels of mGluR2/3 binding (16.8 ± 0.1; n=13) than users of high doses of 
antipsychotics (>450mg/day chlorpromazine equivalent) (13.5 ± 0.7; n=16), no 
significance was given after correction for age at death (uncorrected F(27,1)=7.72; 
p<0.05; corrected for age at death F(26,1)=2.27; p=0.14). 
 
4. Discussion 
Metabotropic glutamate receptors 2 and 3 have been shown as efficient targets for 
antipsychotic intervention (Patil et al. 2007). We therefore investigated the receptor 
density of mGluR2/3 in the dlPFC, which has been implicated in the symptomatology 
of schizophrenia, in patients with schizophrenia/schizoaffective diagnosis and 
matched control subjects (Figure 1). No difference in receptor density was found due 
to schizophrenia/schizoaffective diagnosis (Table 1). A strong correlation of 
mGluR2/3 binding density with age at death was found overall and separately for 
patient and control groups (Figure 2). No other variables were correlated after 
correcting for age at death, with and without consideration of DSM-IV diagnosis.  
Our data are consistent with previous results, which showed no changes in protein or 
mRNA expression of mGluR2/3 in the dlPFC of schizophrenia patients compared to 
controls (Crook et al. 2002; Gupta et al. 2005). No differences in mGlu2/3R binding 
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levels between schizophrenia or schizoaffective diagnosed patients additionally 
suggests that this might be common to psychotic illnesses.  
We also did not observe any changes correlated to antipsychotic or antidepressant 
drug treatment. This is in accordance with findings of Gupta et al (2005) and Crook et 
al (2002), who neither detected changes in medicated vs unmedicated schizophrenia 
patients. All studied patient cohorts, including our cohort, showed, however, either 
variations in treatment history or age at death as a confounding factor so that drug 
effects cannot be fully excluded. Still, these data are supported by earlier studies on 
rats, which showed that treatment with haloperidol, clozapine or olanzapine did little 
or not affect mGluR2/3 expression in the frontal cortex (Tascedda et al. 2001). 
Age-related reduction in glutamate receptor binding in post-mortem human brain 
tissues has been demonstrated before (Newell et al. 2005). Specifically for mGluR2/3 
receptors, reduced mRNA and protein expression levels have been shown in healthy 
controls, however, not schizophrenia patients (Colantuoni et al. 2008; Crook et al. 
2002). This is contrasted by other studies on mGluR2/3, which did not observe age-
related effects (Ghose et al. 2009; Gupta et al. 2005). Studies on rats, in comparison, 
have shown rather an increase in mGluR2/3 expression levels with older age 
(Simonyi et al. 2005). Considering the modulatory properties of mGluR2/3 receptors 
on the glutamatergic synapse, these results require further attention. The synaptic 
localization of mGluR2 and mGluR3 can be both pre- and postsynaptic, where they 
function primarily as autoreceptors and are involved in regulation of neurotransmitter 
release and ion channel openings (Swanson et al. 2005; Wieronska and Pilc 2009). It 
was speculated that mGluR2/3 receptors thereby protect neurons from excitotoxicity 
in suppressing excitatory neurotransmission (Swanson et al. 2005). With mGluR2/3 
most likely attenuating synaptic transmission, a reduced availability with increasing 
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age might require other compensatory mechanisms to maintain appropriate 
glutamatergic transmission. No matter if in relation to physiological or pathological 
conditions, receptor densities of other mGluR and modulators of synaptic 
glutamatergic transmission remain therefore to be studied and correlated in the 
present cohort. 
While mGluR2 and mGluR3 receptors have a quite similar distribution in the brain, 
and are believed to have similar modulatory roles in glutamatergic 
neurotransmission, subtype specific receptor changes might be relevant for drug 
action. Whereas the problem of selective measurement of mGluR2 and mGluR3 
protein expression has been resolved (Ghose et al. 2009), selective measurement of 
receptor density remains problematic due to a lack of specific ligands (Harrison et al. 
2008). The radioligand used in our study, [3H]LY354740, targeted both mGluR2 and 
mGluR3. Ghose et al (2009) showed, however, when, using subtype specific 
antibodies, a higher expression of mGluR2 than mGluR3 in the dlPFC of healthy 
controls. In animal studies on mGluR2 and mGluR3 receptor knock-out mice, it was 
additionally found that mGluR2 rather than mGluR3 mediate the actions of the 
therapeutically active mGluR2/3 receptor agonist LY379268 (Woolley et al. 2008); 
indicating that the mGluR2 is more likely to be involved in the therapeutic efficiency in 
schizophrenia pathology. We therefore used a protocol favouring binding to mGluR2 
over mGluR3 (Richards et al. 2005). Whereas this confirmed the data of Crook et al 
(2002), who did not find any differences in mGluR2/3 protein expression, the 
decrease mGluR3 receptor levels observed by Ghose et al (2009) needs to be 
confirmed using a more mGluR3 specific protocol or a specific ligand for receptor 
binding; particularly considering genetic human population studies that suggested 
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that the mGluR3 rather than the mGluR2 are associated with schizophrenia (Harrison 
and Weinberger 2005).  
Our study and studies of others have shown that mGluR2/3 receptors are abundant 
in the dlPFC, where mGluR2/3 agonists might exhibit their potential to treat 
schizophrenia symptoms particularly related to cognitive deficits (Crook et al. 2002; 
Ghose et al. 2009; Gupta et al. 2005). Though, overall findings to date for expression 
levels of mGluR2/3 and receptor density of mGluR2/3, with a bias for mGluR2, in the 
dlPFC showed little or no changes (our results and (Crook et al. 2002; Ghose et al. 
2009)). Corti et al (2007) showed, however, decreased dimerisation of mGluR3 in 
Brodmann area 10 of schizophrenic patients while total mGluR3 expression remained 
unchanged. This indicates that also functional receptor binding for both mGluR2 and 
mGluR3 and their interaction needs to be explored in schizophrenia patients as well 
as in response to mGluR2/3 agonist drug treatment before final conclusions can be 
drawn. On the other hand, considering recent studies on mGluR2 and mGluR3 
mutant mice, limbic rather than cortical brain areas might be of relevance to 
schizophrenia pathology and mGluR2/3 agonist efficiency (Hetzenauer et al. 2008). 
Altogether, the mGluR2/3 receptors are a novel and highly promising target for 
antipsychotic intervention, their way of action, however, remains to be uncovered for 
a better understanding of their potency to treat schizophrenia.  
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Legends 
 
Figure 1: (A) Receptor autoradiographs using [3H]LY354740 to label metabotropic 
glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex (dlPFC) 
of control subjects and schizophrenia/schizoaffective patients, obtained by beta 
imager scanning. No difference in mGluR2/3 density in the dlPFC was found due to 
diagnosis. (B) Addition of the selective mGlu2/3 agonist DCG-IV prevented 
radioactive labelling of mGluR2/3 evidencing the specificity of [3H]LY354740 binding 
to mGluR2/3. (C) Analysis was based on histological identification of the dlPFC 
provided by Weickert et al (for reference see Weickert et al. (2010)). 
 
 
Figure 2: Correlation of metabotropic glutamate receptor 2 and 3 (mGluR2/3) density 
in the dorsolateral prefrontal cortex (dlPFC) of control subjects (CON; open squares) 
and patients with schizophrenia/schizoaffective diagnosis (SCZ, black diamonds) with 
the respective age at death. mGluR2/3 was found lower in older subjects 
independent of schizophrenia diagnosis (R=0.66; p<0.01). 
Figure 1 colour for web (TIF)
Click here to download high resolution image
Figure 1 bw for print (TIF)
Click here to download high resolution image
Figure 2
Click here to download high resolution image
 
 
Table 1: Relative metabotropic glutamate receptor 2 and 3 (mGluR2/3) density in the 
dorsolateral prefrontal cortex (dlPFC) of control subjects vs patients with 
schiozphrenia/schizoaffective diagnosis. 
 
 
 
Controls 
All patients with 
schizophrenia 
or 
schizoaffective  
diagnosis 
 
Patients with 
schizophrenia 
diagnosis 
only 
Patients with 
schizoaffective 
diagnosis only 
Relative mGluR2/3 
density 
(means±SEM) 
14.41           
± 0.05 
14.99                     
± 0.5 
14.79               
± 0.6 
15.87                
± 1.2 
Number of cases 36 33 27 6 
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